Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted therapies. Leveraging multiomic data from ∼2,000 tumor samples (including 316MSS CRCs not previously profiled) representing ∼4,500 molecular profiles and 195,246 single cel...
A. Sadanandam, A. O'Farrell, I. Miller et al.· Cancer Cell· 1 citation
Findings show that resistance to ICI in liver metastases arises from tissue-specific misdirection of immune activation away from productive antitumor immunity, identifying multicellular coordination of the immune response in the metastatic microenvironment as a determinant of therapeutic efficacy.
I. Baraibar, S. Morabito, G. Deuner-Cos et al.· medRxiv· 0 citations
Neoantigen-targeted T-cell therapies require invasive tumor biopsies to identify neoantigens and reactive T cells, limiting their applicability and potentially underestimating tumor heterogeneity. We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole...
Andrea García-Garijo, I. Creus-González, Pierre L. Levy et al.· Cancer Discovery· 0 citations
The Commission developed a value-based resource-stratified implementation framework, a system-readiness assessment tool, a precision oncology workforce competency-based framework, a precision oncology monitoring and evaluation framework, and principles for responsible data sharing and health-system learning.
R. Casolino, J. Mateo, E. D. de Vries et al.· The Lancet Oncology· 11 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.